APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumors Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Solid Tumors Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025198 pages

Choose your research edition.

Industry ResearchSolid Tumors Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumors Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Solid Tumors Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumors Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumors Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Solid Tumors Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Solid Tumors Drugs include Sanofi, Johnson & Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Solid Tumors Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Solid Tumors Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Solid Tumors Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Solid Tumors Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Solid Tumors Drugs Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

AbbVie

AstraZeneca

Hoffmann-La Roche

Daiichi Sankyo

Celgene

Boston Biomedical

Boehringer Ingelheim

BMS

Biogen

Solid Tumors Drugs Segment by Type

Small Molecules

Biologics

Solid Tumors Drugs Segment by Application

Academic and Research Institutes

Hospitals

Clinics

Others

Solid Tumors Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumors Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumors Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumors Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Solid Tumors Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Solid Tumors Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Solid Tumors Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Solid Tumors Drugs Industry Trends Table 2. Solid Tumors Drugs Industry Drivers Table 3. Solid Tumors Drugs Industry Opportunities and Challenges Table 4. Solid Tumors Drugs Industry Restraints Table 5. Global Solid Tumors Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Solid Tumors Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Solid Tumors Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Solid Tumors Drugs Sales Market Share by Manufacturers Table 9. Global Solid Tumors Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Solid Tumors Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Solid Tumors Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Solid Tumors Drugs Manufacturers, Product Type & Application Table 13. Global Solid Tumors Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Solid Tumors Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Small Molecules Table 17. Major Manufacturers of Biologics Table 18. Global Solid Tumors Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Solid Tumors Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Solid Tumors Drugs Sales Market Share by Type (2021-2026) Table 22. Global Solid Tumors Drugs Sales Market Share by Type (2027-2032) Table 23. Global Solid Tumors Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Solid Tumors Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Solid Tumors Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Solid Tumors Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Solid Tumors Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Academic and Research Institutes Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Others Table 32. Global Solid Tumors Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Solid Tumors Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Solid Tumors Drugs Sales Market Share by Application (2021-2026) Table 36. Global Solid Tumors Drugs Sales Market Share by Application (2027-2032) Table 37. Global Solid Tumors Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Solid Tumors Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Solid Tumors Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Solid Tumors Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Solid Tumors Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Solid Tumors Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Solid Tumors Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Solid Tumors Drugs Sales Market Share by Region (2021-2026) Table 45. Global Solid Tumors Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Solid Tumors Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Solid Tumors Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Solid Tumors Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Solid Tumors Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Solid Tumors Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Solid Tumors Drugs Revenue Market Share by Region (2027-2032) Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sanofi Solid Tumors Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Solid Tumors Drugs Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Solid Tumors Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck Solid Tumors Drugs Product Portfolio Table 83. Merck Recent Development Table 84. Eli Lilly Company Information Table 85. Eli Lilly Business Overview Table 86. Eli Lilly Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Eli Lilly Solid Tumors Drugs Product Portfolio Table 88. Eli Lilly Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer Solid Tumors Drugs Product Portfolio Table 93. Pfizer Recent Development Table 94. GSK Company Information Table 95. GSK Business Overview Table 96. GSK Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. GSK Solid Tumors Drugs Product Portfolio Table 98. GSK Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Bayer Solid Tumors Drugs Product Portfolio Table 103. Bayer Recent Development Table 104. AbbVie Company Information Table 105. AbbVie Business Overview Table 106. AbbVie Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. AbbVie Solid Tumors Drugs Product Portfolio Table 108. AbbVie Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca Solid Tumors Drugs Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Hoffmann-La Roche Company Information Table 115. Hoffmann-La Roche Business Overview Table 116. Hoffmann-La Roche Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Hoffmann-La Roche Solid Tumors Drugs Product Portfolio Table 118. Hoffmann-La Roche Recent Development Table 119. Daiichi Sankyo Company Information Table 120. Daiichi Sankyo Business Overview Table 121. Daiichi Sankyo Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Daiichi Sankyo Solid Tumors Drugs Product Portfolio Table 123. Daiichi Sankyo Recent Development Table 124. Celgene Company Information Table 125. Celgene Business Overview Table 126. Celgene Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Celgene Solid Tumors Drugs Product Portfolio Table 128. Celgene Recent Development Table 129. Boston Biomedical Company Information Table 130. Boston Biomedical Business Overview Table 131. Boston Biomedical Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Boston Biomedical Solid Tumors Drugs Product Portfolio Table 133. Boston Biomedical Recent Development Table 134. Boehringer Ingelheim Company Information Table 135. Boehringer Ingelheim Business Overview Table 136. Boehringer Ingelheim Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Boehringer Ingelheim Solid Tumors Drugs Product Portfolio Table 138. Boehringer Ingelheim Recent Development Table 139. BMS Company Information Table 140. BMS Business Overview Table 141. BMS Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. BMS Solid Tumors Drugs Product Portfolio Table 143. BMS Recent Development Table 144. Biogen Company Information Table 145. Biogen Business Overview Table 146. Biogen Solid Tumors Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Biogen Solid Tumors Drugs Product Portfolio Table 148. Biogen Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Solid Tumors Drugs Distributors List Table 152. Solid Tumors Drugs Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Solid Tumors Drugs Product Image Figure 2. Global Solid Tumors Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Tumors Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Solid Tumors Drugs Sales (2021-2032) & (K Units) Figure 5. Global Solid Tumors Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Solid Tumors Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Small Molecules Image Figure 9. Biologics Image Figure 10. Global Solid Tumors Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Solid Tumors Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Solid Tumors Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Solid Tumors Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Solid Tumors Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Solid Tumors Drugs Revenue Market Share by Type (2021-2032) Figure 16. Academic and Research Institutes Image Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Solid Tumors Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Solid Tumors Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Solid Tumors Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Solid Tumors Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Solid Tumors Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Solid Tumors Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 40. China Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Solid Tumors Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Solid Tumors Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Solid Tumors Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Solid Tumors Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Solid Tumors Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Solid Tumors Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Solid Tumors Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Solid Tumors Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Solid Tumors Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Academic and Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • AbbVie
  • AstraZeneca
  • Hoffmann-La Roche
  • Daiichi Sankyo
  • Celgene
  • Boston Biomedical
  • Boehringer Ingelheim
  • BMS
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Solid Tumors Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Solid Tumors Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Solid Tumors Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Solid Tumors Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Solid Tumors Drugs Market Dynamics
  1. 2.1 Solid Tumors Drugs Industry Trends
  2. 2.2 Solid Tumors Drugs Industry Drivers
  3. 2.3 Solid Tumors Drugs Industry Opportunities and Challenges
  4. 2.4 Solid Tumors Drugs Industry Restraints
3 Solid Tumors Drugs Market by Manufacturers
  1. 3.1 Global Solid Tumors Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Solid Tumors Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Solid Tumors Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Solid Tumors Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Solid Tumors Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Solid Tumors Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Solid Tumors Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Solid Tumors Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Solid Tumors Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Solid Tumors Drugs Tier 1, Tier 2, and Tier 3
4 Solid Tumors Drugs Market by Type
  1. 4.1 Solid Tumors Drugs Type Introduction
  2. 4.1.1 Small Molecules
  3. 4.1.2 Biologics
  4. 4.2 Global Solid Tumors Drugs Sales by Type
  5. 4.2.1 Global Solid Tumors Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Solid Tumors Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Solid Tumors Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Solid Tumors Drugs Revenue by Type
  9. 4.3.1 Global Solid Tumors Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Solid Tumors Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Solid Tumors Drugs Revenue Market Share by Type (2021-2032)
5 Solid Tumors Drugs Market by Application
  1. 5.1 Solid Tumors Drugs Application Introduction
  2. 5.1.1 Academic and Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Solid Tumors Drugs Sales by Application
  7. 5.2.1 Global Solid Tumors Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Solid Tumors Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Solid Tumors Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Solid Tumors Drugs Revenue by Application
  11. 5.3.1 Global Solid Tumors Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Solid Tumors Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Solid Tumors Drugs Revenue Market Share by Application (2021-2032)
6 Global Solid Tumors Drugs Sales by Region
  1. 6.1 Global Solid Tumors Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Solid Tumors Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Solid Tumors Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Solid Tumors Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Solid Tumors Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Solid Tumors Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Solid Tumors Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Solid Tumors Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Solid Tumors Drugs Revenue by Region
  1. 7.1 Global Solid Tumors Drugs Revenue by Region
  2. 7.1.1 Global Solid Tumors Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Solid Tumors Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Solid Tumors Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Solid Tumors Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Solid Tumors Drugs Revenue (2021-2032)
  8. 7.2.2 North America Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Solid Tumors Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Solid Tumors Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Solid Tumors Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Solid Tumors Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Solid Tumors Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Solid Tumors Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Solid Tumors Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Solid Tumors Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Solid Tumors Drugs Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Solid Tumors Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK Solid Tumors Drugs Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Solid Tumors Drugs Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Solid Tumors Drugs Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Solid Tumors Drugs Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Hoffmann-La Roche
  62. 8.11.1 Hoffmann-La Roche Company Information
  63. 8.11.2 Hoffmann-La Roche Business Overview
  64. 8.11.3 Hoffmann-La Roche Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hoffmann-La Roche Solid Tumors Drugs Product Portfolio
  66. 8.11.5 Hoffmann-La Roche Recent Developments
  67. 8.12 Daiichi Sankyo
  68. 8.12.1 Daiichi Sankyo Company Information
  69. 8.12.2 Daiichi Sankyo Business Overview
  70. 8.12.3 Daiichi Sankyo Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Solid Tumors Drugs Product Portfolio
  72. 8.12.5 Daiichi Sankyo Recent Developments
  73. 8.13 Celgene
  74. 8.13.1 Celgene Company Information
  75. 8.13.2 Celgene Business Overview
  76. 8.13.3 Celgene Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Solid Tumors Drugs Product Portfolio
  78. 8.13.5 Celgene Recent Developments
  79. 8.14 Boston Biomedical
  80. 8.14.1 Boston Biomedical Company Information
  81. 8.14.2 Boston Biomedical Business Overview
  82. 8.14.3 Boston Biomedical Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boston Biomedical Solid Tumors Drugs Product Portfolio
  84. 8.14.5 Boston Biomedical Recent Developments
  85. 8.15 Boehringer Ingelheim
  86. 8.15.1 Boehringer Ingelheim Company Information
  87. 8.15.2 Boehringer Ingelheim Business Overview
  88. 8.15.3 Boehringer Ingelheim Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim Solid Tumors Drugs Product Portfolio
  90. 8.15.5 Boehringer Ingelheim Recent Developments
  91. 8.16 BMS
  92. 8.16.1 BMS Company Information
  93. 8.16.2 BMS Business Overview
  94. 8.16.3 BMS Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BMS Solid Tumors Drugs Product Portfolio
  96. 8.16.5 BMS Recent Developments
  97. 8.17 Biogen
  98. 8.17.1 Biogen Company Information
  99. 8.17.2 Biogen Business Overview
  100. 8.17.3 Biogen Solid Tumors Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biogen Solid Tumors Drugs Product Portfolio
  102. 8.17.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Solid Tumors Drugs Value Chain Analysis
  2. 9.1.1 Solid Tumors Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Solid Tumors Drugs Production Mode & Process
  6. 9.2 Solid Tumors Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Solid Tumors Drugs Distributors
  9. 9.2.3 Solid Tumors Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst